Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
Annual Reports
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
Financial Info
Overview
Financial Results
Income Statement
Cash Flow
Stock Data
TSX: APS
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
SEDAR
Governance
Overview
Board of Directors
Board Committees
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
20-F
20-F/A
40-F
NT 20-F
Year:
View All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
1998
1997
Date
Form
Description
PDF
XBRL
Pages
11/27/02
NT 20-F
Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
3
Previous
1
2
3
4
Email Alerts
Contacts
RSS News Feed
